SHANG.FOS.PHARM.GR.H YC 1 (F:08HH) — Market Cap & Net Worth
Market Cap & Net Worth: SHANG.FOS.PHARM.GR.H YC 1 (08HH)
SHANG.FOS.PHARM.GR.H YC 1 (F:08HH) has a market capitalization of $1.12 Billion (€958.72 Million) as of June 21, 2026. Listed on the F stock exchange, this Germany-based company holds position #8569 globally and #1110 in its home market, demonstrating a -0.91% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying SHANG.FOS.PHARM.GR.H YC 1's stock price €1.74 by its total outstanding shares 551940500 (551.94 Million). Review 08HH current and long-term liabilities to assess the company's total debt and financial obligations.
SHANG.FOS.PHARM.GR.H YC 1 Market Cap History: 2020 to 2026
SHANG.FOS.PHARM.GR.H YC 1's market capitalization history from 2020 to 2026. Data shows growth from $1.17 Billion to $1.12 Billion (289.86% CAGR).
SHANG.FOS.PHARM.GR.H YC 1 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how SHANG.FOS.PHARM.GR.H YC 1's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.03x
SHANG.FOS.PHARM.GR.H YC 1's market cap is 0.03 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.40x
SHANG.FOS.PHARM.GR.H YC 1's market cap is 0.40 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $1.27 Billion | $39.01 Billion | $4.73 Billion | 0.03x | 0.27x |
| 2022 | $1.31 Billion | $43.95 Billion | $3.73 Billion | 0.03x | 0.35x |
| 2023 | $986.31 Million | $41.40 Billion | $2.39 Billion | 0.02x | 0.41x |
| 2024 | $1.10 Billion | $41.07 Billion | $2.77 Billion | 0.03x | 0.40x |
| 2025 | $1.35 Billion | $41.66 Billion | $3.37 Billion | 0.03x | 0.40x |
Competitor Companies of 08HH by Market Capitalization
Companies near SHANG.FOS.PHARM.GR.H YC 1 in the global market cap rankings as of June 21, 2026.
Key companies related to SHANG.FOS.PHARM.GR.H YC 1 by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #515 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #554 globally with a market cap of $48.78 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #602 globally with a market cap of $45.20 Billion USD ( CN¥308.87 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #627 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #515 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #554 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $42.94 |
| #602 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.20 Billion | CN¥48.42 |
| #627 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €13.50 |
SHANG.FOS.PHARM.GR.H YC 1 Historical Marketcap From 2020 to 2026
Between 2020 and today, SHANG.FOS.PHARM.GR.H YC 1's market cap moved from $1.17 Billion to $ 1.12 Billion, with a yearly change of 289.86%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €1.12 Billion | -17.13% |
| 2025 | €1.35 Billion | +22.93% |
| 2024 | €1.10 Billion | +11.55% |
| 2023 | €986.31 Million | -24.75% |
| 2022 | €1.31 Billion | +3.58% |
| 2021 | €1.27 Billion | +7.72% |
| 2020 | €1.17 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 21st, 2026 the market cap of SHANG.FOS.PHARM.GR.H YC 1 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.12 Billion USD |
| MoneyControl | $1.12 Billion USD |
| MarketWatch | $1.12 Billion USD |
| marketcap.company | $1.12 Billion USD |
| Reuters | $1.12 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About SHANG.FOS.PHARM.GR.H YC 1
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. engages in the pharmaceutical business in Mainland China and internationally. It operates through five segments: Pharmaceuticals, Medical Devices and Medical Diagnosis, Medical Services, Medical Distribution and Retail, and Others. The company is involved in the pharmaceutical manufacturing in the therapeutic areas of solid oncology, including tumor… Read more